SOPH

SOPHiA GENETICS SA Ordinary Shares (SOPH) | Rumor.io

SOPHiA GENETICS SA

SOPH

Attention (50-day avg)0%

Attention rank (50-day avg)#1,932

Bullish sentiment (50-day avg)80%

Price to earnings ratio-7.26

Market capitalization722.7M

Earnings per share-1.16

Dividend yield (TTM)—

Revenue (annual)77.3M

Net income (annual)-79M

Social

What share of all stock conversation is about SOPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

May 11

SOPH is predicted to experience a massive bullish rally with a potential 250% price increase.
The stock is believed to be at its bottom, with some traders suggesting it's a good time to buy.
SOPH's chart setup is considered decent, with price holding above a key trendline, potentially indicating a classic scam pump.

Generated by AI

Sentiment

Of the messages about SOPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	74.1% -25.9	87.08% -1.97
Bearish	—	0% 0	25.9% +25.9	12.92% +1.97

Bullish· Oct 23

SOPH is up 8.61% in the last hour, holding firm above key support, and bulls are back in control.
SOPH is creating a falling wedge pattern and has already broken out, expecting a 150%+ gain.
SOPH is making a bullish falling wedge and breakout, expecting an energetic move to around $0.06000.

Bearish· May 30

The market for $SOPH has been severely impacted, with a 50.3% drop from its launch price of $0.092.
The asset's price has declined significantly due to a combination of factors, including early unlocks, a lack of bid support, and thin volume.
The market structure for $SOPH remains bearish, with lower highs and lows on both 4H and daily timeframes, and a potential move below critical support at $0.052664 may lead to a further decline to $0.0500.

Generated by AI

Topics

Of the messages about SOPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	81.82%	83.46%
Technical Analysis	—	—	18.18%	15.07%
Earnings	—	—	0%	0.89%
Analysts	—	—	0%	0.59%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Aug 5

SOPHiA GENETICS expands its collaboration with AstraZeneca using AI to improve breast cancer patient outcomes.
The partnership will leverage AI to advance breast cancer research and will have a geographic expansion across Europe and North America.
SOPHiA GENETICS reported a revenue beat in Q2 2025, with sales of $18.32M, and an adjusted EPS of $(0.33), missing estimates.

Technical Analysis· Jul 22

Breakout and retest patterns have been identified on SOPH, with a potential target of 0.0404-0.0424-0.0462.
A bullish signal has been triggered, with a predicted short-term price increase to 0.04091, where a strong resistance is expected.
Daily breakout patterns have been observed on SOPH, with multiple buy signals and a target range of 0.0404-0.0424-0.0462.

Generated by AI

Community

Of the messages about SOPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	30.57%	20.55%
Newcomers	—	100%	69.43%	79.45%

Jun 3

Many newcomers are focusing on the potential of SOPHiA GENETICS S.A. to continue its upward trend, with some predicting it will reach new highs.
Some traders are discussing the fundamentals and technical analysis (TA) of SOPH, including its chart performance and momentum indicators, to determine its future price movements.
The asset's short-term volatility and momentum are being closely watched, with some users speculating about its potential to be a "loser" or a "winner" in the short term, and others expressing bullish long-term sentiments.

Generated by AI

SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

12d agoYahoo Finance

SOPHiA Genetics: Scaling Phase Begins As U.S. And Pharma Monetization Inflect

13d agoSeeking Alpha

SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise

SOPHiA GENETICS is back in focus as analysts reset their central price views, with fair value moving from US$9.00 to US$9.75. Recent research linking the company’s role in data driven oncology and rare disease diagnostics with Q2 results and higher guidance has supported price targets in a US$9 to US$12 range, while still flagging execution and valuation risk. Read on to see how these shifting targets feed into the broader SOPHiA GENETICS story and how you can track the narrative from...

25d agoYahoo Finance

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

Detailed price information for Sophia Genetics Sa (SOPH-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access

1mo agoYahoo Finance UK

SOPHiA GENETICS Updates Investors With Q2 2026 Form 6-K Filing

Detailed price information for Sophia Genetics Sa (SOPH-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about SOPH also mention

#	Name	Attention
1	Conductor Global Equity Value ETFCGV	0%new
2	Humacyte Inc.HUMA	0%0
3	Sensient Technologies CorporationSXT	0%0
4	Bank OZKOZK	0%new
5	LGTY - Logility Supply Chain Solutions, Inc.	——
6	MFS Municipal Income TrustMFM	0%0
7	LombardBARD	0%new
8	CARV - Carver Bancorp, Inc.	——
9	Orochi NetworkON	0%new
10	USXUSX	0%new

SOPHiA GENETICS SA Ordinary Shares

Healthcare
Health Information Services

SOPHiA GENETICS SA Ordinary Shares is the equity of SOPHiA GENETICS, a healthcare technology company focused on data-driven medicine and life sciences research. The company develops cloud-native software that analyzes complex genomic and multimodal healthcare data, helping hospitals, laboratories, and biopharmaceutical organizations generate actionable insights across cancer, rare disorders, and other diagnostic areas. Its core platform, SOPHiA DDM, supports the interpretation of data from multiple testing modalities, including genomics, radiomics, clinical information, biological data, and digital pathology. SOPHiA GENETICS serves a global network of healthcare and research institutions that use its software to streamline analysis and support more coordinated diagnostic workflows. Headquartered in Rolle, Switzerland, SOPHiA GENETICS operates at the intersection of healthcare, artificial intelligence, and precision medicine, making it an important provider of digital tools for modern clinical and research environments.

Website

Location

La PiEce 12

Rolle, 1180

Switzerland

Social

What share of all stock conversation is about SOPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

May 11

SOPH is predicted to experience a massive bullish rally with a potential 250% price increase.
The stock is believed to be at its bottom, with some traders suggesting it's a good time to buy.
SOPH's chart setup is considered decent, with price holding above a key trendline, potentially indicating a classic scam pump.

Generated by AI

Sentiment

Of the messages about SOPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	74.1% -25.9	87.08% -1.97
Bearish	—	0% 0	25.9% +25.9	12.92% +1.97

Bullish· Oct 23

SOPH is up 8.61% in the last hour, holding firm above key support, and bulls are back in control.
SOPH is creating a falling wedge pattern and has already broken out, expecting a 150%+ gain.
SOPH is making a bullish falling wedge and breakout, expecting an energetic move to around $0.06000.

Bearish· May 30

The market for $SOPH has been severely impacted, with a 50.3% drop from its launch price of $0.092.
The asset's price has declined significantly due to a combination of factors, including early unlocks, a lack of bid support, and thin volume.
The market structure for $SOPH remains bearish, with lower highs and lows on both 4H and daily timeframes, and a potential move below critical support at $0.052664 may lead to a further decline to $0.0500.

Generated by AI

Topics

Of the messages about SOPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	81.82%	83.46%
Technical Analysis	—	—	18.18%	15.07%
Earnings	—	—	0%	0.89%
Analysts	—	—	0%	0.59%
Controversies	—	—	0%	0%
Macro	—	—	0%	0%

Announcements· Aug 5

SOPHiA GENETICS expands its collaboration with AstraZeneca using AI to improve breast cancer patient outcomes.
The partnership will leverage AI to advance breast cancer research and will have a geographic expansion across Europe and North America.
SOPHiA GENETICS reported a revenue beat in Q2 2025, with sales of $18.32M, and an adjusted EPS of $(0.33), missing estimates.

Technical Analysis· Jul 22

Breakout and retest patterns have been identified on SOPH, with a potential target of 0.0404-0.0424-0.0462.
A bullish signal has been triggered, with a predicted short-term price increase to 0.04091, where a strong resistance is expected.
Daily breakout patterns have been observed on SOPH, with multiple buy signals and a target range of 0.0404-0.0424-0.0462.

Generated by AI

Community

Of the messages about SOPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	30.57%	20.55%
Newcomers	—	100%	69.43%	79.45%

Jun 3

Many newcomers are focusing on the potential of SOPHiA GENETICS S.A. to continue its upward trend, with some predicting it will reach new highs.
Some traders are discussing the fundamentals and technical analysis (TA) of SOPH, including its chart performance and momentum indicators, to determine its future price movements.
The asset's short-term volatility and momentum are being closely watched, with some users speculating about its potential to be a "loser" or a "winner" in the short term, and others expressing bullish long-term sentiments.

Generated by AI

SOPHiA GENETICS SA

Social

May 11

Sentiment

Bullish· Oct 23

Bearish· May 30

Topics

Announcements· Aug 5

Technical Analysis· Jul 22

Community

Jun 3

News

SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?

SOPHiA Genetics: Scaling Phase Begins As U.S. And Pharma Monetization Inflect

SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access

SOPHiA GENETICS Updates Investors With Q2 2026 Form 6-K Filing

Also Discussed

SOPHiA GENETICS SA Ordinary Shares

Company Information

Location

News

SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?

SOPHiA Genetics: Scaling Phase Begins As U.S. And Pharma Monetization Inflect

SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access

SOPHiA GENETICS Updates Investors With Q2 2026 Form 6-K Filing

Also Discussed

Social

May 11

Sentiment

Bullish· Oct 23

Bearish· May 30

Topics

Announcements· Aug 5

Technical Analysis· Jul 22

Community

Jun 3